Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1001 in Advanced Non-small Cell Lung Cancer With c-Met Dysregulation
NCT04258033Phase 2Completed
- Sponsor
- Beijing Pearl Biotechnology Co., Ltd.
- Start
- Jan 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Pearl Biotechnology Co., Ltd. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2020; status: completed.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04258033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258033.